An Investigator And Subject-Blind Phase 1 Study To Characterize the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Subjects.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs PF 4995274 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
- 19 Jan 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 19 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.